FindTrial
Sign In

gp160 Vaccine (Immuno-AG)

BIOLOGICAL9 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsHIV Seronegativity

Phase 1

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)
CompletedNCT00000968
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1993-08-31Updated: 2021-11-04
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
CompletedNCT00000822
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1999-05-31Target: 46Updated: 2021-10-29
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
CompletedNCT00000957
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1993-08-31Updated: 2021-11-04
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals
CompletedNCT00000633
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1998-10-31Target: 55Updated: 2021-11-02
A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen
CompletedNCT00000782
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1996-10-31Target: 50Updated: 2021-11-04
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
CompletedNCT00001043
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, HIV Seronegativity
End: 1997-05-31Updated: 2021-11-04
A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
CompletedNCT00001037
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1995-05-31Updated: 2021-11-04
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
CompletedNCT00001026
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1994-12-31Target: 56Updated: 2021-11-04
A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
CompletedNCT00001056
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1994-10-31Updated: 2021-11-04